Affinage

PKMYT1

Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase · UniProt Q99640

Round 2 corrected
Length
499 aa
Mass
54.5 kDa
Annotated
2026-04-28
130 papers in source corpus 39 papers cited in narrative 37 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PKMYT1 (Myt1) is a membrane-associated dual-specificity kinase that phosphorylates CDK1 (Cdc2) preferentially on Thr14 and, to a lesser extent, Tyr15 to inhibit CDK1/cyclin B activity, thereby maintaining G2/prophase arrest in both mitotic and meiotic cell cycles (PMID:7569953, PMID:9001210, PMID:9268380). Anchored to the endoplasmic reticulum and Golgi via a C-terminal hydrophobic domain, PKMYT1 sequesters CDK1/cyclin B in the cytoplasm and is inactivated at M-phase entry through sequential phosphorylation by multiple upstream kinases — including CDK1/XRINGO, p90Rsk, Plk1, Akt, and SGK — acting on distinct sites in its C-terminal regulatory domain (PMID:9724639, PMID:15692562, PMID:20362450, PMID:11802161, PMID:31537708). Beyond G2/M regulation, PKMYT1 is required for Golgi and ER reassembly during mitotic exit through inhibition of cyclin B1/B2–CDK1 complexes and contributes to DNA damage checkpoint recovery independently of WEE1 (PMID:18378775, PMID:23146904). PKMYT1 functions redundantly with WEE1 in normal cells, but this redundancy is lost in cancers with CCNE1 amplification or other oncogenic alterations, creating synthetic lethal vulnerabilities exploitable by the selective inhibitor RP-6306 (lunresertib) (PMID:35444283, PMID:26673326, PMID:35880755).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1995 High

    Identification of Myt1 as the kinase responsible for CDK1 Thr14 phosphorylation resolved the long-standing question of which enzyme mediates this inhibitory modification, distinguishing Myt1 from Wee1 (which preferentially targets Tyr15).

    Evidence cDNA cloning and immunodepletion of Xenopus egg extracts with in vitro kinase assays

    PMID:7569953

    Open questions at the time
    • Mammalian ortholog not yet characterized
    • Regulation of Myt1 activity unknown
  2. 1997 High

    Characterization of human PKMYT1 established its ER/Golgi localization through a C-terminal hydrophobic domain and confirmed cyclin-dependent, CDK1-selective substrate specificity, providing the spatial framework for how PKMYT1 restrains mitotic entry from endomembranes.

    Evidence In vitro kinase assays, deletion mutagenesis, and immunofluorescence in HeLa cells; parallel substrate specificity studies with CDK2/CDK4

    PMID:9001210 PMID:9268380

    Open questions at the time
    • Mechanism of substrate specificity for CDK1 over CDK2/CDK4 undefined
    • How membrane anchoring contributes to CDK1 sequestration not tested
  3. 1998 High

    Discovery that p90Rsk and Pin1 bind the C-terminal regulatory domain of Myt1 in a phosphorylation-dependent manner revealed the first upstream inhibitory inputs and suggested multisite phosphorylation as the mechanism for Myt1 inactivation at M-phase entry.

    Evidence GST pulldown, co-immunoprecipitation from Xenopus oocytes, in vitro kinase assay; MPM-2 co-IP from mitotic cell extracts

    PMID:9499405 PMID:9724639

    Open questions at the time
    • Precise phosphorylation sites on Myt1 targeted by p90Rsk not mapped
    • Functional consequence of Pin1 binding not determined
  4. 1999 High

    Demonstration that both kinase-active and kinase-dead Myt1 sequester CDK1/cyclin B1 in the cytoplasm established a catalysis-independent scaffolding function and showed that the C-terminal 63 amino acids mediate substrate recruitment.

    Evidence Overexpression in human osteosarcoma cells, cyclin B1 trafficking assays, in vitro kinase assays with C-terminal deletions

    PMID:10373560 PMID:10504341

    Open questions at the time
    • Whether cytoplasmic sequestration is physiologically separable from kinase activity in vivo unknown
    • Structural basis of the C-terminal docking interaction unresolved
  5. 2002 High

    Identification of Akt/PKB and Mos as direct Myt1 kinases linked growth-factor and hormonal signaling pathways to Myt1 inactivation, explaining how extracellular cues trigger meiotic G2/M transition through convergent phosphorylation of Myt1.

    Evidence In vitro kinase assay, microinjection of Akt constructs in starfish oocytes; co-IP and in vivo phosphorylation in Xenopus oocytes

    PMID:11802161 PMID:11959823

    Open questions at the time
    • Whether Akt directly phosphorylates mammalian PKMYT1 in somatic cells not tested
    • Mos–Myt1 interaction confirmed only in single lab
  6. 2003 High

    Mapping of four Plk1 phosphorylation sites on Myt1's C-terminus and identification of the TSAP6 interaction expanded the regulatory network, establishing Plk1 as a direct mitotic inactivator of Myt1.

    Evidence In vitro kinase assay with systematic mutagenesis, gel mobility shift in nocodazole-arrested cells; yeast two-hybrid and co-IP for TSAP6

    PMID:12606722 PMID:12738781

    Open questions at the time
    • Functional consequence of TSAP6–Myt1 interaction in cell cycle not established
    • Whether all four Plk1 sites are required in vivo not determined
  7. 2005 High

    Elucidation of the CDK1-Thr478-Plx1 docking mechanism showed how CDK1 primes its own inhibitor for Polo-like kinase recognition, creating a positive feedback loop that ensures irreversible mitotic commitment.

    Evidence Site-directed mutagenesis of Thr478, co-IP, in vitro kinase assay, and embryo injection rescue in Xenopus

    PMID:15692562

    Open questions at the time
    • Whether this docking mechanism operates equivalently in mammalian somatic cells not tested
  8. 2008 High

    Discovery that Myt1 is required for Golgi and ER reassembly during mitotic exit and that XRINGO-activated CDKs target distinct Myt1 sites revealed post-mitotic functions and an additional layer of substrate-specific regulation beyond canonical cyclin-CDK complexes.

    Evidence siRNA knockdown with electron microscopy of Golgi/ER in mammalian cells; in vitro kinase assay with XRINGO-CDK and mutagenesis in Xenopus oocytes

    PMID:18378775 PMID:18951089

    Open questions at the time
    • How Myt1 distinguishes cyclin B1 versus B2 targeting for organelle reassembly unknown
    • Whether XRINGO-CDK regulation of Myt1 occurs in somatic cells untested
  9. 2010 High

    Ordered two-step inactivation model (CDK1/XRINGO then p90Rsk) and compartment-specific cooperation with Wee1B in mouse oocytes resolved how meiotic cells achieve switch-like Myt1 inactivation while maintaining spatial control over CDK1 activation.

    Evidence Sequential mutagenesis of five p90Rsk sites with co-IP in Xenopus oocytes; siRNA in mouse oocytes with live imaging and GVBD assays

    PMID:20083600 PMID:20362450

    Open questions at the time
    • Whether this two-step model applies to somatic mitotic entry not established
  10. 2012 High

    Demonstration that Myt1 controls DNA damage checkpoint recovery rate and that MEK1 inactivates Myt1 to fragment the Golgi for mitotic entry placed PKMYT1 at the intersection of checkpoint signaling, endomembrane remodeling, and mitotic commitment.

    Evidence siRNA knockdown with CHK1/WEE1 inhibitors and time-lapse microscopy; epistasis with MEK1 inhibition in Golgi fragmentation assays

    PMID:23146904 PMID:23241949

    Open questions at the time
    • Identity of the kinase downstream of MEK1 that directly phosphorylates Myt1 not resolved
    • Whether checkpoint recovery role is relevant in all cell types unknown
  11. 2015 High

    Genome-wide CRISPR screens revealed that PKMYT1 and WEE1 are functionally redundant in normal neural stem cells but this redundancy is lost in glioblastoma stem cells, establishing the first cancer-specific vulnerability for PKMYT1.

    Evidence Genome-wide CRISPR-Cas9 KO screens with in vitro and in vivo validation in GSCs

    PMID:26673326

    Open questions at the time
    • Molecular basis for why oncogenic signaling disrupts PKMYT1/WEE1 redundancy not defined
  12. 2019 High

    Identification of PKMYT1 upregulation as a resistance mechanism to WEE1 inhibitors and of SGK as a direct Myt1 kinase further consolidated the view of PKMYT1 as a critical node integrating multiple upstream signals with therapeutic relevance.

    Evidence Drug-resistant cell line generation with CDK1 activity assays; in vitro kinase assay and epistasis in starfish oocytes

    PMID:31537708 PMID:31594837

    Open questions at the time
    • Whether dual WEE1/PKMYT1 inhibition overcomes resistance without intolerable toxicity unknown
  13. 2022 High

    The synthetic lethal interaction between CCNE1 amplification and PKMYT1 inhibition was mechanistically attributed to unscheduled CDK1 activation causing premature mitosis during S phase, and the selective inhibitor RP-6306 demonstrated in vivo efficacy, establishing PKMYT1 as a druggable target in CCNE1-amplified cancers.

    Evidence Genome-scale CRISPR synthetic lethality screens, RP-6306 biochemical and structural characterization, xenograft models

    PMID:35444283 PMID:35880755

    Open questions at the time
    • Patient response biomarkers beyond CCNE1 amplification not fully defined
    • Long-term resistance mechanisms to RP-6306 unknown
  14. 2023 High

    Combined WEE1 and PKMYT1 inhibition synergistically induces replication catastrophe and inflammatory STAT1 signaling in ovarian cancer, demonstrating that dual targeting can overcome the functional redundancy between these kinases.

    Evidence Combination drug treatment with CDK activity, DNA damage markers, and organoid models

    PMID:37325550

    Open questions at the time
    • In vivo tolerability of dual WEE1/PKMYT1 inhibition not established
    • Whether STAT1 activation contributes to antitumor immunity not tested
  15. 2024 High

    Crystal structures of PKMYT1 with inhibitors identified the non-conserved gatekeeper residue Thr187 as the key determinant of selectivity over WEE1, and studies in breast cancer and pancreatic cancer expanded the therapeutic context to LMW-E-driven tumors and identified PLK1 as a downstream effector.

    Evidence X-ray co-crystal structures, molecular dynamics, LMW-E overexpression/depletion models, CRISPR screens in PDAC, PDX models

    PMID:37345529 PMID:38570712 PMID:39163619 PMID:39186665

    Open questions at the time
    • Full-length PKMYT1 structure including transmembrane domain not solved
    • Mechanism by which PKMYT1 regulates PLK1 expression is unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: the structural basis of full-length membrane-embedded PKMYT1 function, the molecular determinants that dictate why PKMYT1/WEE1 redundancy is lost specifically in oncogene-driven contexts, and the clinical efficacy and resistance landscape of PKMYT1 inhibitors as monotherapy or in combination.
  • No full-length structure including transmembrane and C-terminal regulatory domains
  • Molecular basis of redundancy loss with WEE1 in cancer undefined
  • Clinical response and resistance mechanisms in patients unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 7 GO:0098772 molecular function regulator activity 5
Localization
GO:0005794 Golgi apparatus 3 GO:0005783 endoplasmic reticulum 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-1640170 Cell Cycle 9 R-HSA-162582 Signal Transduction 4 R-HSA-1474165 Reproduction 3 R-HSA-1852241 Organelle biogenesis and maintenance 2 R-HSA-73894 DNA Repair 2
Partners
AKT1CCNA2CCNB1CCNB2CDK1PIN1PLK1RPS6KA1

Evidence

Reading pass · 37 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1995 Xenopus Myt1 is a membrane-associated kinase that phosphorylates Cdc2 on both Thr14 and Tyr15, making it the predominant Thr14-specific kinase in Xenopus egg extracts; it contains a putative transmembrane segment and its activity is highly regulated during the cell cycle. cDNA cloning, in vitro kinase assay, immunodepletion of Xenopus egg extracts Science High 7569953
1997 Human Myt1 (PKMYT1) preferentially phosphorylates Cdc2 on Thr14 (rather than Tyr15) in a cyclin-dependent manner and localizes to the endoplasmic reticulum and Golgi complex; deletion of its hydrophobic membrane-targeting domain (outside the catalytic domain) redirects it to the nucleus. In vitro kinase assay, immunofluorescence microscopy, deletion mutagenesis in HeLa cells Molecular and Cellular Biology High 9001210
1997 Human Myt1 phosphorylates and inactivates Cdc2-containing cyclin complexes (but not Cdk2 or Cdk4 complexes), remains membrane-bound throughout the cell cycle, becomes hyperphosphorylated during M phase arrest, and can be phosphorylated by Cdc2/cyclin B1 in vitro (without loss of Myt1 kinase activity). In vitro kinase assay, immunoprecipitation, cell cycle synchronization with flow cytometry Journal of Biological Chemistry High 9268380
1998 In Xenopus oocytes, p90Rsk (activated downstream of MAPK) binds the C-terminal regulatory domain of Myt1, phosphorylates its C-terminus, and downregulates Myt1 inhibitory activity on Cdc2/cyclin B in vitro; Myt1 preferentially associates with hyperphosphorylated p90Rsk, and complexes are detected in mature oocyte immunoprecipitates. GST pulldown, in vitro kinase assay, co-immunoprecipitation from Xenopus oocytes The EMBO Journal High 9724639
1999 The C-terminal domain (last 63 amino acids) of Myt1 is required for recruitment of Cdc2/cyclin B1 complexes and for efficient in vitro phosphorylation of Cdc2; overexpression of either kinase-active or kinase-inactive Myt1 sequesters Cdc2/cyclin B1 in the cytoplasm blocking nuclear-cytoplasmic shuttling of cyclin B1 and causing G2 delay; the C-terminal domain interacts with Pin1 in a phosphorylation-dependent manner. Overexpression studies in human osteosarcoma cells and S. pombe, in vitro kinase assay, cyclin B1 trafficking assays, co-immunoprecipitation Journal of Cell Science / Molecular and Cellular Biology High 10373560 10504341
2002 In starfish oocytes, Akt/PKB phosphorylates and downregulates Myt1, switching the balance between Cdc25C and Wee1/Myt1 activities to trigger the initial activation of cyclin B-Cdc2 at the meiotic G2/M transition; Myt1 is identified as a new Akt substrate and Akt acts as an M-phase initiator through this mechanism. In vitro kinase assay, microinjection of constitutively active/dominant-negative Akt in starfish oocytes, immunoblotting Nature Cell Biology High 11802161
2002 Mos interacts directly with Myt1 in Xenopus oocyte extracts and triggers Myt1 phosphorylation in vivo even in the absence of MAPK activation, identifying Myt1 as a direct Mos target that mediates MPF activation independently of the MAPK cascade. Co-immunoprecipitation from oocyte extracts, in vivo phosphorylation assays, GVBD readout Development Medium 11959823
2003 Plk1 phosphorylates Myt1 in vitro and in mitotic cells; a consensus Plk1 phosphorylation motif (hydrophobic at +1, acidic at -2) was identified and four C-terminal Plk1 sites on Myt1 were mapped; a Myt1-4A mutant (all four sites alanine) shows no gel mobility shift in nocodazole-treated cells. In vitro kinase assay with systematically mutated peptides, site-directed mutagenesis, gel mobility shift in nocodazole-arrested cells Journal of Biological Chemistry High 12738781
2003 TSAP6 (a p53-inducible transmembrane protein) physically associates with the Myt1 kinase as shown by yeast two-hybrid, GST pulldown, and in vivo co-immunoprecipitation; TSAP6 overexpression enhances Myt1 activity. Yeast two-hybrid, GST/in vitro pull-down, co-immunoprecipitation, kinase activity assay PNAS Medium 12606722
2005 After fertilization of Xenopus eggs, Polo-like kinase Plx1 (rather than p90Rsk) interacts with and inhibits Myt1; Cdc2 phosphorylates Myt1 on Thr478 during M phase to create a docking site for Plx1's polo-box domain; Plx1 phosphorylates Myt1 and inhibits its kinase activity both in vitro and in vivo; p90Rsk-mediated phosphorylation of Myt1 during meiosis largely prevents Plx1 binding. Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis of Thr478, embryo injection rescue experiments The EMBO Journal High 15692562
2006 In C. elegans, the Myt1 ortholog WEE-1.3 maintains CDK-1 inhibitory phosphorylation to prevent precocious oocyte maturation; depletion causes premature oocyte maturation, aberrant meiotic spindle organization, and fertilization incompetence; co-depletion with CDK-1 suppresses all phenotypes, confirming CDK-1 is the major WEE-1.3 target in vivo. RNAi depletion in C. elegans, epistasis (double depletion), immunofluorescence of meiotic spindles Development High 16421191
2008 Myt1 is essential for Golgi and ER assembly during telophase in mammalian cells; both cyclin B1 and cyclin B2 (not just Cdc2/CDK1 itself) serve as Myt1 targets required for proper membrane organelle reassembly during mitotic exit. siRNA knockdown, time-lapse microscopy, electron microscopy of Golgi/ER, cell fractionation Journal of Cell Biology High 18378775
2008 XRINGO-activated CDKs phosphorylate specific residues in the regulatory domain of Myt1 (three Ser sites) that are poorly phosphorylated by CDK/cyclin complexes; phosphorylation of these sites inhibits Myt1 activity, and their mutation makes Myt1 resistant to CDK/XRINGO-mediated inhibition, demonstrating substrate specificity differences between XRINGO- and cyclin-activated CDKs. In vitro kinase assay, site-directed mutagenesis, Xenopus oocyte microinjection Molecular Cell High 18951089
2009 JNK1 (but not JNK2) directly interacts with and phosphorylates Myt1 ex vivo and in vitro; JNK1-mediated phosphorylation of Myt1 promotes UVA-induced apoptosis and caspase-3 cleavage; JNK1-deficient cells show suppressed Myt1 phosphorylation and reduced apoptosis after UVA. Co-immunoprecipitation, in vitro kinase assay, JNK1/JNK2 knockout MEFs, caspase cleavage assays Molecular and Cellular Biology High 19204086
2010 In mouse oocytes, Wee1B and Myt1 function in distinct subcellular compartments to maintain meiotic arrest; Wee1B is nuclear and Myt1 is cytoplasmic/membrane-associated; down-regulation of either alone causes only partial meiotic resumption and both must be depleted for complete G2/M entry; mislocalized Wee1B or Myt1 cannot maintain meiotic arrest; Cdc25B translocates from cytoplasm to nucleus and Wee1B is exported to cytoplasm just before GVBD. siRNA knockdown in mouse oocytes, live imaging of localization, subcellular fractionation, GVBD assays Journal of Cell Biology High 20083600
2010 Two-step inactivation of Myt1 during Xenopus oocyte maturation: CDK1/XRINGO phosphorylates Myt1 early, downregulating its activity and facilitating recruitment of p90Rsk; p90Rsk then phosphorylates five additional sites on Myt1, and Myt1 phosphorylated by p90Rsk can no longer interact with CDK1/cyclin B, preventing re-inhibition of CDK1 after meiosis I entry. In vitro kinase assay, site-directed mutagenesis of five p90Rsk sites, co-immunoprecipitation, Xenopus oocyte microinjection Current Biology High 20362450
2011 In fully grown Xenopus oocytes, Myt1 is essential for maintaining prophase I arrest; upon progesterone stimulation, upregulated Cyclin B neosynthesis leads to rapid inactivating phosphorylation of Myt1 mediated by Cdc2, without significant contribution from Mos/MAPK or Plx1; the balance between Myt1 inhibitory activity and Cyclin B synthesis is the critical determinant of meiotic resumption. Myt1 depletion in Xenopus oocytes, cyclin B synthesis inhibition, phosphorylation analysis, meiotic resumption assays Development High 21795279
2012 MYT1 has a rate-determining role in DNA damage checkpoint recovery: depletion of MYT1 causes precocious mitotic entry when checkpoint is abrogated by CHK1 or WEE1 inhibitors, indicating MYT1 contributes to recovery independently of WEE1; MYT1 kinase activity is high during checkpoint activation and reduced during recovery; MYT1 depletion alone does not affect normal cell growth but potentiates DNA damage to inhibit growth in clonogenic and xenograft models. siRNA knockdown, time-lapse microscopy, CHK1/WEE1 inhibitor treatment, clonogenic survival assays, tumor xenograft models Oncogene High 23146904
2012 MEK1 inactivates Myt1 to fragment the Golgi in G2 and promote mitotic entry; knockdown of Myt1 eliminates the requirement for MEK1 in Golgi fragmentation and rescues the mitotic delay caused by MEK1 inhibition; MEK1-mediated phosphorylation of Myt1 requires another kinase but is independent of RSK, Plk, and CDK1. siRNA knockdown, permeabilized cell Golgi fragmentation assay, MEK1 inhibitor treatment, epistasis experiments The EMBO Journal High 23241949
2015 PKMYT1 acts redundantly with WEE1 to inhibit cyclin B-CDK1 activity via CDK1-Y15 phosphorylation and to promote timely completion of mitosis in normal neural stem cells; in glioblastoma stem-like cells (GSCs), this redundancy is lost (likely due to oncogenic signaling), causing GSC-specific lethality upon PKMYT1 loss. Genome-wide CRISPR-Cas9 KO screens, in vitro and in vivo validation, CDK1-Y15 phosphorylation analysis Cell Reports High 26673326
2016 In Drosophila spermatocytes, Myt1 inhibition of Cyclin A/Cdk1 (distinct from Cyclin B/Cdk1) is essential for fusome integrity and centriole engagement during premeiotic G2 arrest; myt1 mutant phenotypes (multipolar spindles, fusome disruption, premature centriole disengagement) are suppressed by Cyclin A depletion or ectopic Wee1 expression and phenocopied by a Cdk1F phosphorylation-resistant mutant. Drosophila genetics, myt1 null mutants, epistasis with Cyclin A depletion and Cdk1F allele, immunofluorescence Molecular Biology of the Cell High 27170181
2019 Myt1 and Wee1 kinases are both capable of phosphorylating and inhibiting Cdk1/cyclin B; cancer cells with intrinsic adavosertib (Wee1 inhibitor) resistance have higher Myt1 levels; cells with acquired resistance after adavosertib treatment also upregulate Myt1; downregulating Myt1 restores Cdk1 activity and adavosertib sensitivity, establishing Myt1 upregulation as a mechanism of acquired Wee1 inhibitor resistance. In vitro kinase assay, drug resistance selection, siRNA knockdown, CDK1 activity assays Cancer Research High 31594837
2019 SGK directly phosphorylates both Cdc25 and Myt1 to trigger cyclin B-Cdk1 activation at the meiotic G2/M transition in starfish oocytes; SGK is activated by cooperation between the Gβγ-PI3K pathway and an atypical Gβγ pathway downstream of hormonal stimulation. In vitro kinase assay, microinjection of dominant-negative/constitutively active constructs in starfish oocytes, pathway inhibitors Journal of Cell Biology High 31537708
2022 CCNE1 amplification creates synthetic lethality with PKMYT1 inhibition; PKMYT1 inhibitor RP-6306 causes unscheduled CDK1 activation selectively in CCNE1-overexpressing cells, promoting premature mitosis during DNA synthesis; CCNE1 overexpression disrupts CDK1 homeostasis at least partly through early activation of the MMB-FOXM1 mitotic transcriptional program; RP-6306 shows single-agent activity and durable tumor regression combined with gemcitabine in CCNE1-amplified models. Genome-scale CRISPR-Cas9 synthetic lethality screens, selective inhibitor RP-6306, CDK1 phosphorylation assays, xenograft tumor models, transcriptional program analysis Nature High 35444283
2022 ALKBH5 demethylase suppresses PKMYT1 mRNA expression in an m6A-dependent manner; ALKBH5 knockdown increases PKMYT1 mRNA stability through IGF2BP3 (an m6A reader) binding to PKMYT1 mRNA m6A sites, promoting gastric cancer invasion and migration; PKMYT1 promotes invasion/migration downstream of this epigenetic regulatory axis. MeRIP-seq, RNA pulldown with mass spectrometry, RNA immunoprecipitation, lung metastasis mouse model Molecular Cancer High 35114989
2022 RP-6306, an orally bioavailable and selective PKMYT1 inhibitor, was developed via structure-based drug design; the compound selectively inhibits PKMYT1 over WEE1 and other kinases, inhibits CDK1 phosphorylation at Thr14/Tyr15, and demonstrates efficacy in CCNE1-amplified xenograft models. Structure-based drug design, in vitro kinase assay, selectivity profiling, xenograft tumor models Journal of Medicinal Chemistry High 35880755
2017 PKMYT1 activates β-catenin/TCF signaling in hepatocellular carcinoma by binding to and inactivating GSK3β, promoting HCC cell growth, migration, and EMT. Co-immunoprecipitation, GSK3β kinase assay, β-catenin/TCF reporter, shRNA knockdown, xenograft models Experimental Cell Research Medium 28648520
2019 MCRS1 physically interacts with PKMYT1 in gastric cancer cells as shown by immunoprecipitation; the two proteins co-localize in the cytoplasm; MCRS1 overexpression suppresses PKMYT1 expression and inhibits GC cell proliferation, invasion, and migration. Yeast two-hybrid (initial identification), co-immunoprecipitation, immunofluorescence co-localization Cellular Signalling Medium 30953699
2021 PKMYT1 binds to cyclin A2 (CCNA2) as shown by co-immunoprecipitation in OSCC cells; PKMYT1 knockdown reduces CCNA2 expression and inhibits proliferation, colony formation, migration, invasion, and EMT in oral squamous cell carcinoma cells. Co-immunoprecipitation, shRNA knockdown, cell proliferation and invasion assays Oncology Letters Low 35069872
2022 PKMYT1 directly binds AKT1 and abrogates AKT1 activation in lung adenocarcinoma cells in a manner dependent on its tyrosine and threonine kinase activity; PKMYT1 knockdown increases AKT1 phosphorylation and promotes cell cycle progression, proliferation, migration, and invasion. Co-immunoprecipitation, kinase-dead mutant analysis, AKT1 phosphorylation assays, RNA-seq Cellular Oncology Low 36350496
2023 Combined WEE1 and PKMYT1 inhibition synergistically promotes CDK activation, exacerbates DNA replication stress and replication catastrophe, and activates inflammatory STAT1 signaling in high-grade serous ovarian cancer cells and organoids. Combination drug treatment (WEE1i + PKMYT1i), CDK activity assays, DNA damage markers, organoid models NAR Cancer High 37325550
2024 PKMYT1 functions as an oncogene in pancreatic ductal adenocarcinoma beyond its canonical CDK1-phosphorylating role: it regulates PLK1 expression and phosphorylation; TP53 function and PRKDC activation modulate sensitivity to PKMYT1 inhibition. Genome-wide CRISPR screens, PKMYT1 ablation (genetic and pharmacological), PLK1 expression/phosphorylation analysis, PDX models EMBO Molecular Medicine Medium 38570712
2024 X-ray co-crystal structure of PKMYT1 with inhibitors confirms that key binding interactions with residues Asp251 and Tyr121 enhance potency and selectivity; the non-conserved gatekeeper residue Thr187 (vs. Asn376 in WEE1) in the hinge domain is a critical determinant of RP-6306 selectivity for PKMYT1 over WEE1. X-ray crystallography of PKMYT1-inhibitor complexes, molecular dynamics simulations, binding free energy calculations Journal of Medicinal Chemistry / Journal of Biomolecular Structure and Dynamics High 37345529 39163619
2024 Low-molecular weight cyclin E (LMW-E) upregulates PKMYT1 expression and protein stability in triple-negative breast cancer, increasing CDK1 phosphorylation; PKMYT1 inhibition with RP-6306 elicits LMW-E-dependent antitumor effects by accelerating premature mitotic entry, inhibiting replication fork restart, and enhancing DNA damage and apoptosis. Immunoblotting, LMW-E overexpression/depletion, PKMYT1 inhibitor treatment, replication fork assays, xenograft and transgenic murine mammary tumor models Cancer Research High 39186665
2011 In vitro, human PKMYT1 only phosphorylates protein substrates (not peptides), in contrast to Wee1; Myt1 is insensitive to staurosporine in binding assays, suggesting a distinctive ATP-binding pocket. Fluorescence polarization immunoassays, immunoblotting, molecular dynamics simulations Bioorganic & Medicinal Chemistry Letters Medium 22189141
1998 Pin1 associates with Myt1 (and other mitotic kinases including Wee1, Plk1, Cdc25, Cdc27) in a phosphorylation-dependent and mitosis-specific manner through Ser/Thr-Pro motifs recognized by MPM-2 antibody; this interaction was confirmed in both human cells and Xenopus extracts. Co-immunoprecipitation from mitotic cell extracts, MPM-2 immunoprecipitation, Xenopus extract binding Genes & Development Medium 9499405
2025 Combining PKMYT1 inhibitor lunresertib (RP-6306) with ATR inhibitor camonsertib synergistically increases CDK1 activation, triggering premature mitosis, DNA damage, and apoptosis in a CCNE1-dependent manner; this combination produces durable antitumor activity and reduces metastasis in CCNE1-amplified ovarian and endometrial cancer PDX models. Combination drug studies, CDK1 activation assays, DNA damage markers, patient-derived xenograft models Nature Communications High 40169546

Source papers

Stage 0 corpus · 130 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2015 The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 1118 26186194
2017 Architecture of the human interactome defines protein communities and disease networks. Nature 1085 28514442
2015 A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 1015 26496610
2020 A reference map of the human binary protein interactome. Nature 849 32296183
2003 Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature genetics 754 14702039
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2018 High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies. Molecular cell 580 29395067
1995 Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science (New York, N.Y.) 575 7569953
2015 A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface. Cell 433 26638075
2022 OpenCell: Endogenous tagging for the cartography of human cellular organization. Science (New York, N.Y.) 432 35271311
2010 Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science (New York, N.Y.) 421 20360068
2005 Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome research 409 16344560
2021 A proximity-dependent biotinylation map of a human cell. Nature 339 34079125
1998 The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes & development 315 9499405
1998 A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1. The EMBO journal 296 9724639
1997 The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Molecular and cellular biology 294 9001210
2006 Phosphoproteome analysis of the human mitotic spindle. Proceedings of the National Academy of Sciences of the United States of America 281 16565220
2003 Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. The Journal of biological chemistry 281 12738781
2009 Docking motif-guided mapping of the interactome of protein phosphatase-1. Chemistry & biology 269 19389623
1997 Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. The Journal of biological chemistry 243 9268380
1996 X-MyT1, a Xenopus C2HC-type zinc finger protein with a regulatory function in neuronal differentiation. Cell 203 8980226
2022 Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification. Molecular cancer 190 35114989
2013 The protein interaction landscape of the human CMGC kinase group. Cell reports 174 23602568
2002 Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition. Nature cell biology 174 11802161
2022 CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature 169 35444283
2017 Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. Molecules (Basel, Switzerland) 166 29168755
2020 AMPK, a Regulator of Metabolism and Autophagy, Is Activated by Lysosomal Damage via a Novel Galectin-Directed Ubiquitin Signal Transduction System. Molecular cell 152 31995728
2015 Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell reports 149 26673326
2020 A High-Density Human Mitochondrial Proximity Interaction Network. Cell metabolism 148 32877691
1999 The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression. Journal of cell science 138 10504341
2019 Mapping the proximity interaction network of the Rho-family GTPases reveals signalling pathways and regulatory mechanisms. Nature cell biology 137 31871319
2017 RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is required for ubiquitination. BMC biology 135 29117863
2004 The sequence and analysis of duplication-rich human chromosome 16. Nature 130 15616553
2010 Wee1B, Myt1, and Cdc25 function in distinct compartments of the mouse oocyte to control meiotic resumption. The Journal of cell biology 125 20083600
2021 LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway. Molecular cancer 118 34856993
2004 Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer biology & therapy 117 14726685
2023 ESCRT-dependent STING degradation inhibits steady-state and cGAMP-induced signalling. Nature communications 104 36739287
1999 Overproduction of human Myt1 kinase induces a G2 cell cycle delay by interfering with the intracellular trafficking of Cdc2-cyclin B1 complexes. Molecular and cellular biology 103 10373560
2005 Myt1 family recruits histone deacetylase to regulate neural transcription. Journal of neurochemistry 101 15935060
2006 Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Molecular & cellular proteomics : MCP 96 17192257
1997 Myelin transcription factor 1 (Myt1) of the oligodendrocyte lineage, along with a closely related CCHC zinc finger, is expressed in developing neurons in the mammalian central nervous system. Journal of neuroscience research 96 9373037
2010 A genome-wide association study of the metabolic syndrome in Indian Asian men. PloS one 95 20694148
2003 The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proceedings of the National Academy of Sciences of the United States of America 95 12606722
2020 Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism. Nature metabolism 92 32694731
2004 Myelin transcription factor 1 (Myt1) modulates the proliferation and differentiation of oligodendrocyte lineage cells. Molecular and cellular neurosciences 89 14962745
2020 Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases. Molecular cell 88 32707033
2017 The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. Nature communications 86 29180619
2008 Myt1 and Ngn3 form a feed-forward expression loop to promote endocrine islet cell differentiation. Developmental biology 74 18394599
2012 The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene 69 23146904
2006 The C. elegans Myt1 ortholog is required for the proper timing of oocyte maturation. Development (Cambridge, England) 69 16421191
2005 The Polo-like kinase Plx1 interacts with and inhibits Myt1 after fertilization of Xenopus eggs. The EMBO journal 66 15692562
2002 A new role for Mos in Xenopus oocyte maturation: targeting Myt1 independently of MAPK. Development (Cambridge, England) 62 11959823
2014 Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. Journal of chemical information and modeling 60 24490903
2007 Loss of Myt1 function partially compromises endocrine islet cell differentiation and pancreatic physiological function in the mouse. Mechanisms of development 58 17928203
2022 Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306. Journal of medicinal chemistry 56 35880755
1997 Myt1: a Wee1-type kinase that phosphorylates Cdc2 on residue Thr14. Progress in cell cycle research 56 9552418
2016 Mutations in MYT1, encoding the myelin transcription factor 1, are a rare cause of OAVS. Journal of medical genetics 53 27358179
2016 MyT1 Counteracts the Neural Progenitor Program to Promote Vertebrate Neurogenesis. Cell reports 53 27705795
2019 Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition. Cancer research 51 31594837
2008 Myt1 protein kinase is essential for Golgi and ER assembly during mitotic exit. The Journal of cell biology 46 18378775
2017 PKMYT1 promoted the growth and motility of hepatocellular carcinoma cells by activating beta-catenin/TCF signaling. Experimental cell research 41 28648520
2006 Identification of both Myt-1 and Wee-1 as necessary mediators of the p21-independent inactivation of the cdc-2/cyclin B1 complex and growth inhibition of TRAMP cancer cells by genistein. The Prostate 39 16924665
2020 ESC-sEVs Rejuvenate Aging Hippocampal NSCs by Transferring SMADs to Regulate the MYT1-Egln3-Sirt1 Axis. Molecular therapy : the journal of the American Society of Gene Therapy 38 33038325
2017 A novel de novo mutation in MYT1, the unique OAVS gene identified so far. European journal of human genetics : EJHG 38 28612832
2007 Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS. Glia 38 17330875
2010 A two-step inactivation mechanism of Myt1 ensures CDK1/cyclin B activation and meiosis I entry. Current biology : CB 37 20362450
2019 Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis. Cell proliferation 36 31837068
2020 PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target. Gene 35 32234541
2002 Ectopic expression of the Drosophila Cdk1 inhibitory kinases, Wee1 and Myt1, interferes with the second mitotic wave and disrupts pattern formation during eye development. Genetics 35 12072468
2014 Identification of myelin transcription factor 1 (MyT1) as a subunit of the neural cell type-specific lysine-specific demethylase 1 (LSD1) complex. The Journal of biological chemistry 33 24828497
2002 Dominant mutations in the Caenorhabditis elegans Myt1 ortholog wee-1.3 reveal a novel domain that controls M-phase entry during spermatogenesis. Development (Cambridge, England) 33 12397109
2019 SGK phosphorylates Cdc25 and Myt1 to trigger cyclin B-Cdk1 activation at the meiotic G2/M transition. The Journal of cell biology 32 31537708
2020 PKMYT1 as a Potential Target to Improve the Radiosensitivity of Lung Adenocarcinoma. Frontiers in genetics 30 32411179
2020 PKMYT1 Promotes Gastric Cancer Cell Proliferation and Apoptosis Resistance. OncoTargets and therapy 30 32801781
2011 A critical balance between Cyclin B synthesis and Myt1 activity controls meiosis entry in Xenopus oocytes. Development (Cambridge, England) 30 21795279
2012 MEK1 inactivates Myt1 to regulate Golgi membrane fragmentation and mitotic entry in mammalian cells. The EMBO journal 29 23241949
2011 A putative transcription factor MYT1 is required for female fertility in the ascomycete Gibberella zeae. PloS one 29 21984921
2004 Keratinocyte G2/M growth arrest by 1,25-dihydroxyvitamin D3 is caused by Cdc2 phosphorylation through Wee1 and Myt1 regulation. The Journal of investigative dermatology 29 15175024
2008 Meiotic inactivation of Xenopus Myt1 by CDK/XRINGO, but not CDK/cyclin, via site-specific phosphorylation. Molecular cell 27 18951089
2009 c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer. Molecular and cellular biology 26 19204086
2008 Drosophila myt1 is the major cdk1 inhibitory kinase for wing imaginal disc development. Genetics 26 18940789
2019 A Myt1 family transcription factor defines neuronal fate by repressing non-neuronal genes. eLife 25 31386623
2014 An RNAi-based suppressor screen identifies interactors of the Myt1 ortholog of Caenorhabditis elegans. G3 (Bethesda, Md.) 24 25298536
2018 Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. Journal of cellular biochemistry 23 29291346
2005 Drosophila Myt1 is a Cdk1 inhibitory kinase that regulates multiple aspects of cell cycle behavior during gametogenesis. Development (Cambridge, England) 23 16107480
2023 Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma. NAR cancer 22 37325550
2020 PKMYT1 aggravates the progression of ovarian cancer by targeting SIRT3. European review for medical and pharmacological sciences 22 32495859
1997 High-grade human brain tumors exhibit increased expression of myelin transcription factor 1 (MYT1), a zinc finger DNA-binding protein. Journal of neuropathology and experimental neurology 22 9210873
2020 MYT1 role in the microtia-craniofacial microsomia spectrum. Molecular genetics & genomic medicine 21 32871052
2019 Effects of MCRS1 on proliferation, migration, invasion, and epithelial mesenchymal transition of gastric cancer cells by interacting with Pkmyt1 protein kinase. Cellular signalling 21 30953699
2016 Myt1 inhibition of Cyclin A/Cdk1 is essential for fusome integrity and premeiotic centriole engagement in Drosophila spermatocytes. Molecular biology of the cell 21 27170181
2008 Mental retardation in a girl with a subtelomeric deletion on chromosome 20q and complete deletion of the myelin transcription factor 1 gene (MYT1). Clinical genetics 21 18341605
2002 NZF-2b is a novel predominant form of mouse NZF-2/MyT1, expressed in differentiated neurons especially at higher levels in newly generated ones. Mechanisms of development 21 12351189
2018 Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. European journal of medicinal chemistry 20 30388464
2025 Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Nature communications 19 40169546
2018 Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochimica et biophysica acta. Gene regulatory mechanisms 19 30312684
2002 Identification of Drosophila Myt1 kinase and its role in Golgi during mitosis. Cellular signalling 19 11882391
2011 In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase. Bioorganic & medicinal chemistry letters 18 22189141
2024 Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. EMBO molecular medicine 17 38570712
2023 Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer. Journal of medicinal chemistry 17 38146659
2017 Viral-mediated overexpression of the Myelin Transcription Factor 1 (MyT1) in the dentate gyrus attenuates anxiety- and ethanol-related behaviors in rats. Psychopharmacology 16 28303373
2013 A fluorescence anisotropy-based Myt1 kinase binding assay. Assay and drug development technologies 15 24229357
2011 JLK1486, a Bis 8-Hydroxyquinoline-Substituted Benzylamine, Displays Cytostatic Effects in Experimental Gliomas through MyT1 and STAT1 Activation and, to a Lesser Extent, PPARγ Activation. Translational oncology 15 21633668
2018 Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II. Bioorganic & medicinal chemistry 14 29941193
2003 Myelin transcription factor 1 (MyT1) immunoreactivity in infants with periventricular leukomalacia. Brain research. Developmental brain research 14 12524179
2024 PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular cancer therapeutics 13 38781103
2021 PKMYT1 regulates the proliferation and epithelial-mesenchymal transition of oral squamous cell carcinoma cells by targeting CCNA2. Oncology letters 13 35069872
2012 Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay. European journal of medicinal chemistry 13 22770610
2009 First total synthesis of 1,2-dipalmitoyl-3-(N-palmitoyl-6'-amino-6'-deoxy-alpha-D-glucosyl)-sn-glycerol--a glycoglycerolipid of a marine alga with a high inhibitor activity against human Myt1-kinase. Carbohydrate research 13 19555926
2024 Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer research 12 39186665
2024 Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial. Journal of medicinal chemistry 12 39383322
2022 PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity. Cellular oncology (Dordrecht, Netherlands) 12 36350496
2012 Synthesis of glycoglycerolipid of 1,2-dipalmitoyl-3-(N-palmitoyl-6'-amino-6'-deoxy-α-D-glucosyl)-sn-glycerol and its analogues, inhibitors of human Myt1-kinase. Carbohydrate research 12 22578528
2024 Myt1 kinase inhibitors - Insight into structural features, offering potential frameworks. Chemico-biological interactions 11 38331334
2023 Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors. Frontiers in cell and developmental biology 11 38020882
2020 MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex. Oncogene 11 32251364
2024 PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 10 38442372
2024 Structure-Based Drug Design of 2-Amino-[1,1'-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1-Amplified Breast Cancer. Journal of medicinal chemistry 10 39163619
2023 Transcription factor TEAD4 facilitates glycolysis and proliferation of gastric cancer cells by activating PKMYT1. Molecular and cellular probes 9 37729973
2022 KDM2B mediates the Wnt/β-catenin pathway through transcriptional activation of PKMYT1 via microRNA-let-7b-5p/EZH2 to affect the development of non-small cell lung cancer. Experimental cell research 9 35580699
2021 The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies. Translational lung cancer research 9 35070764
2012 Isolation of a novel Saccharophagus species (Myt-1) capable of degrading a variety of seaweeds and polysaccharides. MicrobiologyOpen 9 22950007
2011 A tool for examining the role of the zinc finger myelin transcription factor 1 (Myt1) in neural development: Myt1 knock-in mice. Transgenic research 9 21267777
2025 Myt1 Kinase: An Emerging Cell-Cycle Regulator for Cancer Therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research 8 39821288
2024 Discovery of pyrrolopyrimidinone derivatives as potent PKMYT1 inhibitors for the treatment of cancer. European journal of medicinal chemistry 8 39515174
2023 ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer. Cellular oncology (Dordrecht, Netherlands) 8 36988891
2023 Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1. Journal of biomolecular structure & dynamics 8 37345529
2022 Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma. Biochemical and biophysical research communications 8 36512849